Screener
Gilead Sciences GILD Sofosbuvir/Velpatasvir — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Total HIV | 4,659 | 640 | 393 | 5,693 | 4,096 | 624 | 368 | 5,088 |
| Liver Disease | ||||||||
| Livdelzi | 147 | 20 | — | 167 | 74 | 4 | — | 78 |
| Sofosbuvir/Velpatasvir(3) | 142 | 81 | 80 | 303 | 184 | 81 | 76 | 342 |
| Vemlidy | 124 | 13 | 152 | 289 | 122 | 13 | 117 | 252 |
| Other Liver Disease(4) | 20 | 79 | 19 | 118 | 33 | 72 | 19 | 123 |
| Total Liver Disease | 433 | 193 | 251 | 877 | 413 | 170 | 211 | 795 |
| Veklury | 14 | 2 | 7 | 23 | 51 | 19 | 50 | 121 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
- Gilead Sciences (GILD) reported sofosbuvir/velpatasvir — total revenues of $303M in Q2 2026.
- How has Gilead Sciences's sofosbuvir/velpatasvir — total revenues changed year-over-year?
- Gilead Sciences's sofosbuvir/velpatasvir — total revenues decreased by 11.4% year-over-year, from $342M to $303M.
- What is the long-term trend for Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's sofosbuvir/velpatasvir — total revenues has grown at a -5.9% compound annual growth rate (CAGR), from $1.53B to $1.27B.
- What does sofosbuvir/velpatasvir — total revenues mean?
- This metric represents the total gross revenue generated from the sale of a specific direct-acting antiviral medication used to treat chronic hepatitis C virus infection. It reflects the market demand, pricing power, and competitive positioning of the company's liver disease therapeutic portfolio. As a key product line, it serves as a primary indicator of the company's ability to monetize its infectious disease franchise and maintain market share against evolving treatment standards.
Ask your AI about Gilead Sciences's sofosbuvir/velpatasvir — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude